Drug Trial Radar · NCT06129851
Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer
Last checked: Nov 20, 2026Latest source record: Nov 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
90
Planned (sponsor's estimate)
Start
Nov 20, 2023
Primary completion
Oct 23, 2025
Study completion Oct 23, 2026
Sponsor
- Lead sponsor
- University of Kansas Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Nov 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial evaluates the best duration for relugolix to be given in combination with radiation therapy when treating patients with high risk prostate cancer. Prostate cancer is a hormonal influenced cancer. Part of the usual treatment for patients with prostate cancer is androgen deprivation therapy (ADT). ADT is used to lower the amount of testosterone in the body, because testosterone appears to help prostate cancer grow. Relugolix works to reduce testosterone levels, which may inhibit proliferation of prostate cancer cells. It is approved by the Food and Drug Administration to treat prostate cancer. Adding relugolix to standard radiation therapy might work better and have fewer side effects than prior forms of hormonal therapy, but the optimal duration of relugolix in combination with radiation is not known.
Conditions
- Stage IIC Prostate Cancer AJCC v8
- Stage III Prostate Cancer AJCC v8
- Stage IV Prostate Cancer AJCC v8
Interventions
Biospecimen CollectionProcedure
Undergo blood sample collection
Bone ScanProcedure
Undergo bone scan
BrachytherapyRadiation
Undergo brachytherapy
Computed TomographyProcedure
Undergo CT
Dual X-ray AbsorptiometryProcedure
Undergo DEXA scan
External Beam Radiation TherapyRadiation
Undergo external beam radiation therapy
Magnetic Resonance ImagingProcedure
Undergo MRI
PSMA PET ScanProcedure
Undergo PSMA PET
Questionnaire AdministrationOther
Ancillary studies
RelugolixDrug
Given PO
Primary outcomes
What the sponsor says the trial is designed to measure.
- Biochemical recurrenceTime frame: Up to 3 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Kansas Cancer Center
Kansas City, Kansas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.